Exploring the Use of Biologics to Control Rising Disease Incidences
The research service aims to analyse and assess the Therapeutic Monoclonal
Antibodies market in Europe. This is performed by analysing the key trends and
dynamics shaping the industry sector in correlation with the market drivers
and restraints. With several key blockbuster drugs losing patent protection
and an immense rise in the rate of disease incidences, the use of monoclonal
antibodies for therapeutics has been on the increase. The tendency towards
biologics has been on the increase during the past decade. This research
service provides an in-depth knowledge of the key European markets by
presenting significant growth opportunities for the existing drugs and those
in the pipeline until 2016.
Table of Contents
1. Executive Summary
Snapshot of the Therapeutic Monoclonal Antibodies Market
Summary
2. Market Overview
Overview of the Therapeutic Monoclonal Antibodies
Overview
3. External Challenges: Drivers and Restraints Monoclonal Antibodies Market
Overview of the Market Drivers and Restraints
Analysis of the Market Drivers and Restraints
4. Forecasts and Trends Monoclonal Antibodies Market
Overview of the Revenue Forecasts and Trends
Analysis of the Market Forecasts and Trends
5. Market Share and Competitive Analysis: Monoclonal Antibodies Market
Overview of the Market Share and Competitive Analysis
Analysis of the Market Share and Competitive Analysis
6. Segmentation by Therapeutics
Segmentation Based on the Area of Therapy
Per cent of Revenue by Segment
Oncology
Autoimmune and Inflammatory
Infectious
Others
7. Regional Analysis of the Monoclonal Antibodies Market
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease